Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 117


Age is not a prognostic variable with autotransplants for multiple myeloma.

Siegel DS, Desikan KR, Mehta J, Singhal S, Fassas A, Munshi N, Anaissie E, Naucke S, Ayers D, Spoon D, Vesole D, Tricot G, Barlogie B.

Blood. 1999 Jan 1;93(1):51-4.


Autologous stem cell transplantation in patients of 70 years and older with multiple myeloma: Results from a matched pair analysis.

Kumar SK, Dingli D, Lacy MQ, Dispenzieri A, Hayman SR, Buadi FK, Rajkumar SV, Litzow MR, Gertz MA.

Am J Hematol. 2008 Aug;83(8):614-7. doi: 10.1002/ajh.21191.


Dose-intensive melphalan with stem cell support (CM regimen) is effective and well tolerated in elderly myeloma patients.

Palumbo A, Triolo S, Baldini L, Callea V, Capaldi A, De Stefano V, Grasso M, Liberati M, Lotesoriere C, Marcenò R, Marmont F, Musto P, Petrucci MT, Spriano M, Pileri A, Boccadoro M.

Haematologica. 2000 May;85(5):508-13.


Cardiovascular toxicity is increased, but manageable, during high-dose chemotherapy and autologous peripheral blood stem cell transplantation for patients aged 60 years and older.

Mileshkin LR, Seymour JF, Wolf MM, Gates P, Januszewicz EH, Joyce P, Prince HM.

Leuk Lymphoma. 2005 Nov;46(11):1575-9.


Autotransplants in multiple myeloma: what have we learned?

Vesole DH, Tricot G, Jagannath S, Desikan KR, Siegel D, Bracy D, Miller L, Cheson B, Crowley J, Barlogie B.

Blood. 1996 Aug 1;88(3):838-47.


Dose-intensive melphalan with stem cell support (MEL100) is superior to standard treatment in elderly myeloma patients.

Palumbo A, Triolo S, Argentino C, Bringhen S, Dominietto A, Rus C, Omedè P, Tarella C, Pileri A, Boccadoro M.

Blood. 1999 Aug 15;94(4):1248-53.


High-dose therapy for refractory multiple myeloma: improved prognosis with better supportive care and double transplants.

Vesole DH, Barlogie B, Jagannath S, Cheson B, Tricot G, Alexanian R, Crowley J.

Blood. 1994 Aug 1;84(3):950-6.


Autologous transplantation in multiple myeloma: a GITMO retrospective analysis on 290 patients. Gruppo Italiano Trapianti di Midollo Osseo.

Majolino I, Vignetti M, Meloni G, Vegna ML, Scimè R, Tringali S, Amaddii G, Coser P, Tribalto M, Raimondi R, Bergonzi C, Sajeva MR, Sica S, Ferrando F, Messina G, Mandelli F.

Haematologica. 1999 Sep;84(9):844-52.


Long-term follow-up after high-dose therapy for high-risk multiple myeloma.

Barlogie B, Jagannath S, Naucke S, Mattox S, Bracy D, Crowley J, Tricot G, Alexanian R.

Bone Marrow Transplant. 1998 Jun;21(11):1101-7.


Age at transplantation and outcome after autologous stem cell transplantation in elderly patients with multiple myeloma.

El Cheikh J, Kfoury E, Calmels B, Lemarie C, Stoppa AM, Bouabdallah R, Coso D, Schiano De Collela JM, Ladaique P, Gastaut JA, Mohty M, Chabannon C, Blaise D.

Hematol Oncol Stem Cell Ther. 2011;4(1):30-6.


[Intensive treatment of multiple myeloma].

Harousseau JL.

Bull Acad Natl Med. 2003;187(2):405-13; discussion 413-5. Review. French.


Salvage autologous or allogeneic transplantation for multiple myeloma refractory to or relapsing after a first-line autograft?

Mehta J, Tricot G, Jagannath S, Ayers D, Singhal S, Siegel D, Desikan K, Munshi N, Fassas A, Mattox S, Vesole D, Crowley J, Barlogie B.

Bone Marrow Transplant. 1998 May;21(9):887-92.


Feasibility and outcome of tandem stem cell autotransplants in multiple myeloma.

Galli M, Nicolucci A, Valentini M, Belfiglio M, Delaini F, Crippa C, Barbui AM, Giussani U, Rambaldi A, Barbui T.

Haematologica. 2005 Dec;90(12):1643-9.


Total therapy with tandem transplants for newly diagnosed multiple myeloma.

Barlogie B, Jagannath S, Desikan KR, Mattox S, Vesole D, Siegel D, Tricot G, Munshi N, Fassas A, Singhal S, Mehta J, Anaissie E, Dhodapkar D, Naucke S, Cromer J, Sawyer J, Epstein J, Spoon D, Ayers D, Cheson B, Crowley J.

Blood. 1999 Jan 1;93(1):55-65.


High dose chemotherapy followed by autologous haemopoietic stem cell transplant in multiple myeloma.

Kumar L, Raju GM, Ganessan K, Shawgi S, Menon H, Wadhwa J, Sharma A, Singh R, Kochupillai V.

Natl Med J India. 2003 Jan-Feb;16(1):16-21.


High-dose therapy and autologous blood stem-cell transplantation compared with conventional treatment in myeloma patients aged 55 to 65 years: long-term results of a randomized control trial from the Group Myelome-Autogreffe.

Fermand JP, Katsahian S, Divine M, Leblond V, Dreyfus F, Macro M, Arnulf B, Royer B, Mariette X, Pertuiset E, Belanger C, Janvier M, Chevret S, Brouet JC, Ravaud P; Group Myelome-Autogreffe..

J Clin Oncol. 2005 Dec 20;23(36):9227-33. Epub 2005 Nov 7.


Autologous stem cell transplantation is safe and feasible in elderly patients with multiple myeloma.

Qazilbash MH, Saliba RM, Hosing C, Mendoza F, Qureshi SR, Weber DM, Wang M, Flosser T, Couriel DR, De Lima M, Kebriaei P, Popat U, Alousi AM, Champlin RE, Giralt SA.

Bone Marrow Transplant. 2007 Mar;39(5):279-83. Epub 2007 Jan 29.


High-dose melphalan and granulocyte-macrophage colony-stimulating factor for refractory multiple myeloma.

Barlogie B, Jagannath S, Dixon DO, Cheson B, Smallwood L, Hendrickson A, Purvis JD, Bonnem E, Alexanian R.

Blood. 1990 Aug 15;76(4):677-80.


Combinations of cytogenetics and international scoring system can predict poor prognosis in multiple myeloma after high-dose chemotherapy and autologous stem cell transplantation.

Inamoto Y, Kurahashi S, Imahashi N, Fukushima N, Adachi T, Kinoshita T, Tsushita K, Miyamura K, Naoe T, Sugiura I.

Am J Hematol. 2009 May;84(5):283-6. doi: 10.1002/ajh.21390.

Supplemental Content

Support Center